Investigates PEG copolymers reducing anti-PEG antibody recognition, indicating potential in nanomedicine.
Anti-PEG antibodies (APAs) lead to accelerated blood clearance of PEGylated drugs and nanocarriers. Randomized PEG (rPEG) reduces APA recognition by randomly incorporating glycidyl methyl ether in PEG. Extending this concept, statistical copolymerization of ethylene oxide with ethyl glycidyl ether (EGE) or isopropyl glycidyl ether (iPGE) was investigated. Copolymers of EO with 13–28 mol % EGE or 6–20 mol % iPGE showed low dispersity (Đ ≤ 1.09). Via online-NMR monitoring, reactivity ratios in DMSO were rEO = 1.39 and rEGE = 0.72 for P(EO-co-EGE) and rEO = 1.35 and riPGE = 0.74 for P(EO-co-iPGE). All copolymers were soluble in PBS buffer at physiological temperatures and noncytotoxic, except for 20% iPGE content, shown by cell viability and immunostimulatory effects on murine splenocytes. All copolymers exhibit significantly reduced APA recognition (ELISA) with stronger effects for the sterically demanding iPGE. The findings highlight mP(EO-co-EGE) and mP(EO-co-iPGE) as promising PEG alternatives for nanomedicine and bioconjugation.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: